Bevacizumab biosimilar - Reliance Life Sciences

Drug Profile

Bevacizumab biosimilar - Reliance Life Sciences

Alternative Names: R TPR 023

Latest Information Update: 19 Feb 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Reliance Life Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Colorectal cancer

Most Recent Events

  • 19 Feb 2016 Bevacizumab biosimilar is still in phase III trial for Colorectal cancer (Metastatic disease, First-line therapy) in India (IV) (CTRI2013-05-003699)
  • 29 May 2013 Biomarkers information updated
  • 28 May 2013 Phase-III clinical trials in Colorectal cancer (Metastatic disease, First-line therapy) in India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top